Logo image of HTBX

HEAT BIOLOGICS INC (HTBX) Stock Price, Quote, News and Overview

NYSEARCA:HTBX - NYSE Arca - US42237K4094 - Common Stock

2.38  +0.01 (+0.42%)

HTBX Quote, Performance and Key Statistics

HEAT BIOLOGICS INC

NYSEARCA:HTBX (5/2/2022, 8:04:01 PM)

2.38

+0.01 (+0.42%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High10.85
52 Week Low2.07
Market Cap61.05M
Shares25.65M
Float24.32M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-17 2022-05-17/bmo
IPO07-24 2013-07-24


HTBX short term performance overview.The bars show the price performance of HTBX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

HTBX long term performance overview.The bars show the price performance of HTBX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of HTBX is 2.38 null. In the past month the price decreased by -22.98%. In the past year, price decreased by -61.92%.

HEAT BIOLOGICS INC / HTBX Daily stock chart

HTBX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.83 342.01B
AMGN AMGEN INC 14.32 152.57B
GILD GILEAD SCIENCES INC 13.34 128.71B
VRTX VERTEX PHARMACEUTICALS INC 1720.21 128.25B
REGN REGENERON PHARMACEUTICALS 13.32 64.50B
ARGX ARGENX SE - ADR 336.79 39.07B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.19B
ONC BEIGENE LTD-ADR N/A 27.55B
BNTX BIONTECH SE-ADR N/A 24.62B
NTRA NATERA INC N/A 20.46B
SMMT SUMMIT THERAPEUTICS INC N/A 18.19B
BIIB BIOGEN INC 7.34 17.70B

About HTBX

Company Profile

HTBX logo image Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 49 full-time employees. The company went IPO on 2013-07-24. The Company’s gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. The firm also develops ANTHIM, a treatment for inhalation anthrax. ANTHIM is used in the United States and Canada and sold under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage. ANTHIM is supplied as single-dose vials for Intravenous Therapy (IV) infusion. ANTHIM is indicated in adult and pediatric patients.

Company Info

HEAT BIOLOGICS INC

627 Davis Drive, Suite 400

Morrisville NORTH CAROLINA 27560 US

CEO: Jeffrey Wolf

Employees: 49

Company Website: http://www.heatbio.com/

Phone: 19192407133.0

HEAT BIOLOGICS INC / HTBX FAQ

What is the stock price of HEAT BIOLOGICS INC today?

The current stock price of HTBX is 2.38 null. The price increased by 0.42% in the last trading session.


What is the ticker symbol for HEAT BIOLOGICS INC stock?

The exchange symbol of HEAT BIOLOGICS INC is HTBX and it is listed on the NYSE Arca exchange.


On which exchange is HTBX stock listed?

HTBX stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for HEAT BIOLOGICS INC stock?

10 analysts have analysed HTBX and the average price target is 11.6 null. This implies a price increase of 387.5% is expected in the next year compared to the current price of 2.38. Check the HEAT BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is HEAT BIOLOGICS INC worth?

HEAT BIOLOGICS INC (HTBX) has a market capitalization of 61.05M null. This makes HTBX a Micro Cap stock.


How many employees does HEAT BIOLOGICS INC have?

HEAT BIOLOGICS INC (HTBX) currently has 49 employees.


What are the support and resistance levels for HEAT BIOLOGICS INC (HTBX) stock?

HEAT BIOLOGICS INC (HTBX) has a support level at 2.33 and a resistance level at 2.38. Check the full technical report for a detailed analysis of HTBX support and resistance levels.


Is HEAT BIOLOGICS INC (HTBX) expected to grow?

The Revenue of HEAT BIOLOGICS INC (HTBX) is expected to grow by 128.57% in the next year. Check the estimates tab for more information on the HTBX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy HEAT BIOLOGICS INC (HTBX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HEAT BIOLOGICS INC (HTBX) stock pay dividends?

HTBX does not pay a dividend.


When does HEAT BIOLOGICS INC (HTBX) report earnings?

HEAT BIOLOGICS INC (HTBX) will report earnings on 2022-05-17, before the market open.


What is the Price/Earnings (PE) ratio of HEAT BIOLOGICS INC (HTBX)?

HEAT BIOLOGICS INC (HTBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.41).


HTBX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HTBX Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to HTBX. While HTBX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HTBX Financial Highlights

Over the last trailing twelve months HTBX reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 9.62% compared to the year before.


Industry RankSector Rank
PM (TTM) -1658.78%
ROA -28.99%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-2600%
Sales Q2Q%2.18%
EPS 1Y (TTM)9.62%
Revenue 1Y (TTM)-28.09%

HTBX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to HTBX. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of -23.7% and a revenue growth 128.57% for HTBX


Ownership
Inst Owners1.57%
Ins Owners5.77%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82
Price Target11.6 (387.39%)
EPS Next Y-23.7%
Revenue Next Year128.57%